- Home
- NVCT vs CRDF Comparison
NVCT vs CRDF Comparison
Compare NVCT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCT
- CRDF
- Stock Information
- Founded
- NVCT 2020
- CRDF 1999
- Country
- NVCT United States
- CRDF United States
- Employees
- NVCT N/A
- CRDF N/A
- Industry
- NVCT Medicinal Chemicals and Botanical Products
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVCT Health Care
- CRDF Health Care
- Exchange
- NVCT Nasdaq
- CRDF Nasdaq
- Market Cap
- NVCT 119.4M
- CRDF 133.5M
- IPO Year
- NVCT 2022
- CRDF N/A
- Fundamental
- Price
- NVCT $4.52
- CRDF $4.26
- Analyst Decision
- NVCT Strong Buy
- CRDF Strong Buy
- Analyst Count
- NVCT 1
- CRDF 3
- Target Price
- NVCT $21.00
- CRDF $10.33
- AVG Volume (30 Days)
- NVCT 94.6K
- CRDF 4.3M
- Earning Date
- NVCT 11-05-2024
- CRDF 11-07-2024
- Dividend Yield
- NVCT N/A
- CRDF N/A
- EPS Growth
- NVCT N/A
- CRDF N/A
- EPS
- NVCT N/A
- CRDF N/A
- Revenue
- NVCT N/A
- CRDF $688,000.00
- Revenue This Year
- NVCT N/A
- CRDF $23.78
- Revenue Next Year
- NVCT N/A
- CRDF N/A
- P/E Ratio
- NVCT N/A
- CRDF N/A
- Revenue Growth
- NVCT N/A
- CRDF 49.57
- 52 Week Low
- NVCT $4.44
- CRDF $1.41
- 52 Week High
- NVCT $12.10
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- NVCT 37.50
- CRDF 60.25
- Support Level
- NVCT $4.48
- CRDF $3.06
- Resistance Level
- NVCT $5.34
- CRDF $5.64
- Average True Range (ATR)
- NVCT 0.37
- CRDF 0.54
- MACD
- NVCT 0.07
- CRDF 0.18
- Stochastic Oscillator
- NVCT 8.89
- CRDF 59.17
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").